Medicine and Dentistry
Acute Lymphoblastic Leukemia
83%
Acute Myeloid Leukemia
68%
Transplantation
52%
Minimal Residual Disease
52%
Overall Survival
50%
Hematopoietic Stem Cell
36%
Cell Transplantation
36%
Chronic Graft Versus Host Disease
32%
Hematopoietic Stem Cell Transplantation
32%
Leukemia
29%
Acute B-Cell Lymphoblastic Leukemia
27%
Functional Genomics
22%
Hematopoiesis
21%
Progression Free Survival
21%
Chimeric Antigen Receptor T-Cell Immunotherapy
20%
B Cell
20%
Allogeneic Hematopoietic Stem Cell Transplantation
19%
Bone Marrow Failure
19%
Drug Response
18%
Biological Marker
18%
CAR T-cell therapy
18%
Acute Lymphocytic Leukemia
18%
Blinatumomab
17%
DNA Methyltransferase 3A
17%
Disease
16%
Vincristine
16%
Rituximab
16%
Etoposide
16%
Pericarditis
16%
Graft Versus Host Reaction
16%
Phosphotransferase Inhibitor
16%
Reduced Intensity Conditioning
16%
Venetoclax
16%
Myelodysplastic Syndrome
16%
Fibroblast Growth Factor Receptor 1
16%
Mediastinal Germ Cell Tumor
16%
In Vitro
16%
Liver Transplantation
16%
Cyclophosphamide
16%
Immunosuppressive Treatment
16%
Serositis
16%
Doxorubicin
16%
Hemophagocytosis
16%
Prednisone
16%
Exudative Retinal Detachment
16%
Allotransplantation
16%
Asparaginase
16%
Thromboprophylaxis
16%
Patient with Non-Hodgkins Lymphoma
16%
Chimeric Antigen Receptor T-Cell Therapy
16%
Keyphrases
Acute Lymphoblastic Leukemia
100%
Minimal Residual Disease
59%
Overall Survival
38%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
36%
Acute Myeloid Leukemia
32%
Graft-versus-host Disease (GvHD)
32%
Older Adults
24%
Relapsed or Refractory
24%
Hematopoietic Cell Transplantation
21%
Next-generation Sequencing
20%
Targeted Therapy
20%
Transplant Outcomes
20%
Bone Marrow Failure
19%
Novel Therapies
18%
Improved Outcomes
18%
T Cell Receptor
17%
Chimeric Antigen Receptor T-cell Therapy
17%
Adult Patients
17%
Clonal Hematopoiesis of Indeterminate Potential
17%
Blinatumomab
17%
BCR-ABL Inhibitors
16%
New Agents
16%
European LeukemiaNet
16%
Reduced-intensity Conditioning
16%
Novel Biomarkers
16%
Clonal Hematopoiesis
16%
Donor-derived
16%
Liver Transplantation
16%
Mediastinal Germ Cell Tumor
16%
In Vivo Efficacy
16%
Leukemia Patients
16%
High-risk Myelodysplastic Syndrome
16%
Molecular Targets
16%
Treatment Toxicity
16%
Concomitant Use
16%
Philadelphia
16%
Adult Acute Lymphoblastic Leukemia
16%
Immunosuppressive Therapy
16%
Frontline Treatment
16%
Hematopoietic Stem Cell Transplantation
16%
Adverse Impact
16%
Hemophagocytosis
16%
DNMT3A mutation
16%
Allogeneic Transplantation
16%
Intermediate Dose
16%
L-asparaginase
16%
Chimeric Antigen Receptor T Cells (CAR-T)
16%
Enoxaparin
16%
Non-Hodgkin Lymphoma
16%
Thromboprophylaxis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
70%
Venetoclax
32%
Chemotherapy
21%
Acute Myeloid Leukemia
20%
Chimeric Antigen Receptor
20%
T Lymphocyte Receptor
19%
Minimal Residual Disease
18%
Remission
18%
Lymphoblastoma
18%
Overall Survival
17%
Blinatumomab
16%
Pericarditis
16%
Navitoclax
16%
Inflammation
16%
Leukemia
16%
Phosphotransferase Inhibitor
16%
Chronic Graft Versus Host Disease
16%
Fibroblast Growth Factor Receptor 1
16%
Asparaginase
16%
Enoxaparin
16%
Nonhodgkin Lymphoma
16%
Clinical Trial
14%
Thrombosis
12%
Progression Free Survival
12%
Immunotherapy
9%
Toxicity and Intoxication
8%
Cytokine Release Syndrome
8%
Syndrome
7%
Disease
7%
Ponatinib
7%
Dasatinib
7%
Protein Tyrosine Kinase Inhibitor
6%
Tolerability
5%
Drug Toxicity
5%
Interferon
5%
Pharmacogenomics
5%
Immunomodulating Agent
5%